SCHEMBL30260537

SCHEMBL30260537

Oc1[nH]c2ccccc2c1N=NC(=S)Nc1ccccc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.85
TDP1 Q9NUW8 6/20 0.85
MEN1 O00255 5/20 0.85
KMT2A Q03164 5/20 0.85
LMNA P02545 5/20 0.85
L3MBTL1 Q9Y468 3/20 0.85
GAA P10253 2/20 0.85
UBE2N P61088 2/20 0.85
HCRTR1 O43613 1/20 0.85
HTT P42858 5/20 0.81
SMN1; SMN2 Q16637 4/20 0.81
KDM4E B2RXH2 1/20 0.79
POLB P06746 1/20 0.79
THRB P10828 1/20 0.79
ATM Q13315 1/20 0.79
RPS6KA1 Q15418 1/20 0.76
CA11 O75493 1/20 0.72
CA1 P00915 1/20 0.72
CA2 P00918 1/20 0.72
CA9 Q16790 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30260542 0.86 MAPT (1.00) MAPTTDP1MEN1KMT2ALMNA
SCHEMBL30260628 0.83 FAAH (0.74) MAPTTDP1MEN1KMT2ALMNA
SCHEMBL23483662 0.83 FAAH (0.74) MAPTTDP1MEN1KMT2ALMNA
SCHEMBL30260530 0.82 MAPT (0.70) MAPTTDP1MEN1KMT2ALMNA
SCHEMBL29562326 0.78 MAPT (1.00) MAPTTDP1MEN1KMT2ALMNA
SCHEMBL30260455 0.77 MAPT (0.86) MAPTTDP1MEN1KMT2ALMNA
SCHEMBL23483677 0.74 MAPT (0.67) MAPTTDP1MEN1KMT2ALMNA
SCHEMBL30260471 0.74 MAPT (0.67) MAPTTDP1MEN1KMT2ALMNA
SCHEMBL23483898 0.72 KMT2A (1.00) MAPTMEN1KMT2ALMNAL3MBTL1
SCHEMBL30260525 0.72 KMT2A (1.00) MAPTMEN1KMT2ALMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230044407-A1 TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER THE TRUSTEES OF DARTMOUTH COLLEGE 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230044407-A1 TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER MYCBP, MYC, TERF2IP MAPT 3232/4885TDP1 1966/4885MEN1 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.